Imatinib Mesylate Tablet, Film Coated
Product Images NDC 0093-7630

8 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 0093-7630). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

New (Image 1)

New (Image 1)
Chemical structure of Imatinib Mesylate, showing the arrangement of aromatic rings, nitrogen atoms, methyl groups, and the mesylate group (CH3SO3H) as part of the molecule.*
FDA Label Image

New (Image 2)

New (Image 2)
A Kaplan-Meier survival curve chart showing the percentage of patients without progression over 72 months since randomization. It compares two treatment arms: Imatinib Mesylate and IFN+Ara-C. The chart includes patient numbers, hazard ratio, confidence intervals, and statistical test results.*
FDA Label Image

Figure2 (Image 3)

Figure2 (Image 3)
A Kaplan-Meier survival curve graph depicting the percentage of patients without progression to AP/BC over months since randomization. It compares two arms: Imatinib Mesylate and IFN+Ara-C, with patient numbers and hazard ratio statistics noted, including a log-rank test p-value indicating significant difference.*
FDA Label Image

New (Image 4)

New (Image 4)
A Kaplan-Meier survival curve graph showing the probability of being alive and recurrence-free over time in months for patients treated with Imatinib 400 mg versus placebo. The graph includes censored data points indicated by circles and plus signs, with numbers of patients at risk listed below the x-axis at key time points.*
FDA Label Image

New (Image 5)

New (Image 5)
A Kaplan-Meier survival curve chart depicting the probability of recurrence-free survival over time in months for two groups treated with Imatinib at 12 months and 36 months. The graph includes censored observations and statistical values such as hazard ratio 0.46 and p-value less than 0.0001.*
FDA Label Image

New (Image 6)

New (Image 6)
A Kaplan-Meier survival curve showing the probability of overall survival over time in months for Imatinib treatment at 12 months and 36 months. The plot includes two groups distinguished by solid and dashed lines, with censored observations marked. Statistical details such as hazard ratio and p-value are also displayed, along with event counts and numbers at-risk at various time points.*
FDA Label Image

1 (Image 7)

1 (Image 7)
Imatinib Mesylate Tablets 100 mg film-coated oral tablets label showing a package of 90 tablets. The label includes the active ingredient amount per tablet, storage instructions, lot and expiration coding area, and the labeler Teva Pharmaceuticals USA, Inc. The product is Rx only, with manufacturing information and handling instructions.*
FDA Label Image

2 (Image 8)

2 (Image 8)
Label for Imatinib Mesylate Tablets 400 mg oral film-coated tablets by Teva Pharmaceuticals USA, Inc. The label includes storage instructions, dosage note, and manufacturing information. The package contains 30 tablets, and the label features the NDC code 0093-7630-56 and the Teva logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.